Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Metastatic ER+ Her2- Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT04563507
What this trial is testing

Combined Immunotherapies in Metastatic ER+ Breast Cancer

Who this might be right for
Breast Cancer
Weill Medical College of Cornell University 102
Testing effectiveness (Phase 2)Study completedNCT00633464
What this trial is testing

Randomized Phase II Study of Ixabepilone Alone and Ixabepilone Plus Cetuximab as First-Line Treatment for Female Subjects With Triple Negative Locally Advanced Non-resectable and/or Metastatic Breast Cancer

Who this might be right for
Triple Negative Locally Advanced Non-resectable Breast CancerMetastatic Breast Cancer
R-Pharm 79
Testing effectiveness (Phase 2)WithdrawnNCT05191004
What this trial is testing

Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC

Who this might be right for
Advanced Breast CancerMetastatic Breast CancerBreast Cancer+5 more
Nuvation Bio Inc.
Not applicableActive Not RecruitingNCT03281902
What this trial is testing

Genetic Analysis in Blood and Tumor Samples From Patients With Advanced or Metastatic Estrogen Receptor Positive and HER2 Negative Breast Cancer Receiving Palbociclib and Endocrine Therapy

Who this might be right for
Advanced Breast CarcinomaLocally Advanced Breast CarcinomaMetastatic Breast Carcinoma+6 more
Mayo Clinic 68
Testing effectiveness (Phase 2)Active Not RecruitingNCT02411656
What this trial is testing

Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy

Who this might be right for
EdemaErythemaEstrogen Receptor Negative+6 more
M.D. Anderson Cancer Center 71
Testing effectiveness (Phase 2)Study completedNCT01989780
What this trial is testing

Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Japan Breast Cancer Research Group 160
Large-scale testing (Phase 3)Active Not RecruitingNCT05654623
What this trial is testing

Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer

Who this might be right for
Advanced Breast Cancer
Pfizer 624
Not applicableAvailableNCT07643831
What this trial is testing

Expanded Access Program to Provide Giredestrant to Participants With ER+, HER2- Early or Locally Advanced/Metastatic Breast Cancer

Who this might be right for
ER+/HER2- Early or Locally Advanced/Metastatic Breast Cancer
Genentech, Inc.
Large-scale testing (Phase 3)UnknownNCT00532727
What this trial is testing

Triple Negative Breast Cancer Trial

Who this might be right for
Breast Cancer
Institute of Cancer Research, United Kingdom 400
Large-scale testing (Phase 3)Active Not RecruitingNCT04711252
What this trial is testing

A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease

Who this might be right for
ER-Positive HER2-Negative Breast Cancer
AstraZeneca 1,370
Testing effectiveness (Phase 2)Study completedNCT01783444
What this trial is testing

A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer.

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 309
Not applicableStudy completedNCT01081600
What this trial is testing

89Zr-trastuzumab PET for Imaging the Effect of HSP90 Inhibition

Who this might be right for
Breast Cancer
University Medical Center Groningen 7
Testing effectiveness (Phase 2)Ended earlyNCT05932667
What this trial is testing

Milademetan and Fulvestrant in GATA3-mutant, ER+HER- Advanced or Metastatic Breast Cancer

Who this might be right for
Advanced or Metastatic Breast Cancer
Institut Curie 1
Testing effectiveness (Phase 2)WithdrawnNCT04220476
What this trial is testing

CIMER: Combined Immunotherapies in Metastatic ER+ Breast Cancer

Who this might be right for
Breast Cancer
Weill Medical College of Cornell University
Testing effectiveness (Phase 2)Study completedNCT02970682
What this trial is testing

SFX-01 in the Treatment and Evaluation of Metastatic Breast Cancer

Who this might be right for
Breast Neoplasm
Evgen Pharma 60
Testing effectiveness (Phase 2)Ended earlyNCT01918306
What this trial is testing

GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer

Who this might be right for
Estrogen Receptor Negative Breast CancerHuman Epidermal Growth Factor 2 Negative Carcinoma of BreastTriple Negative Breast Cancer+3 more
Vanderbilt-Ingram Cancer Center 11
Large-scale testing (Phase 3)Study completedNCT01958021
What this trial is testing

Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer

Who this might be right for
Advanced, Metastatic Breast Cancer
Novartis Pharmaceuticals 668
Testing effectiveness (Phase 2)Study completedNCT01964924
What this trial is testing

Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer

Who this might be right for
Estrogen Receptor NegativeHER2/Neu NegativeInvasive Breast Carcinoma+4 more
National Cancer Institute (NCI) 37
Testing effectiveness (Phase 2)Study completedNCT02491983
What this trial is testing

Palbociclib in Combination With Fulvestrant or Letrozole in Patients With ER+, HER2- Advanced Breast Cancer

Who this might be right for
Metastatic Breast Cancer
MedSIR 486
Testing effectiveness (Phase 2)Study completedNCT04352777
What this trial is testing

Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer

Who this might be right for
Metastatic Breast CancerLocally Advanced Breast CancerHormone Receptor Positive Tumor
Duke University 18
Next Page